Nanhua Bio Medicine Co Ltd
Landfar Bio-medicine Co., Ltd operates as a biomedical technology company. It operates in two segments, Biomedicine, and Energy Saving and Environmental Protection. The Biomedicine segment engages in the provision of stem cell, immune cell storage and technical services, and medical device trade. The Energy Saving and Environmental Protection segment is involved in the external energy management … Read more
Nanhua Bio Medicine Co Ltd (000504) - Total Liabilities
Latest total liabilities as of September 2025: CN¥479.30 Million CNY
Based on the latest financial reports, Nanhua Bio Medicine Co Ltd (000504) has total liabilities worth CN¥479.30 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Nanhua Bio Medicine Co Ltd - Total Liabilities Trend (1989–2024)
This chart illustrates how Nanhua Bio Medicine Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Nanhua Bio Medicine Co Ltd Competitors by Total Liabilities
The table below lists competitors of Nanhua Bio Medicine Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cre8 Direct Ningbo Co Ltd
SHE:300703
|
China | CN¥1.03 Billion |
|
Jiangxi Wannianqing Cement Co Ltd
SHE:000789
|
China | CN¥5.86 Billion |
|
MBB INDUSTRIES
XETRA:MBB
|
Germany | €421.02 Million |
|
Angel Studios, Inc.
NYSE:ANGX
|
USA | $159.83 Million |
|
Chongqing Sulian Plastic Co. Ltd. A
SHE:301397
|
China | CN¥732.46 Million |
|
Mastek Limited
NSE:MASTEK
|
India | ₹13.57 Billion |
|
HOSHF
PINK:HOSHF
|
USA | $105.03 Billion |
|
Huali Industries
SHG:603038
|
China | CN¥1.23 Billion |
Liability Composition Analysis (1989–2024)
This chart breaks down Nanhua Bio Medicine Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.98 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nanhua Bio Medicine Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nanhua Bio Medicine Co Ltd (1989–2024)
The table below shows the annual total liabilities of Nanhua Bio Medicine Co Ltd from 1989 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥326.17 Million | -30.11% |
| 2023-12-31 | CN¥466.71 Million | -1.37% |
| 2022-12-31 | CN¥473.18 Million | -13.80% |
| 2021-12-31 | CN¥548.93 Million | +30.18% |
| 2020-12-31 | CN¥421.66 Million | +174.03% |
| 2019-12-31 | CN¥153.87 Million | -34.51% |
| 2018-12-31 | CN¥234.95 Million | -14.98% |
| 2017-12-31 | CN¥276.34 Million | +24.80% |
| 2016-12-31 | CN¥221.43 Million | +61.32% |
| 2015-12-31 | CN¥137.26 Million | +37.81% |
| 2014-12-31 | CN¥99.61 Million | -18.57% |
| 2013-12-31 | CN¥122.32 Million | +26.29% |
| 2012-12-31 | CN¥96.86 Million | -33.70% |
| 2011-12-31 | CN¥146.09 Million | +16.23% |
| 2010-12-31 | CN¥125.69 Million | -53.09% |
| 2009-12-31 | CN¥267.95 Million | +3.71% |
| 2008-12-31 | CN¥258.36 Million | +11.21% |
| 2007-12-31 | CN¥232.31 Million | +19.93% |
| 2006-12-31 | CN¥193.70 Million | -4.19% |
| 2005-12-31 | CN¥202.16 Million | +26.33% |
| 2004-12-31 | CN¥160.03 Million | -7.10% |
| 2003-12-31 | CN¥172.25 Million | -26.00% |
| 2002-12-31 | CN¥232.77 Million | -16.48% |
| 2001-12-31 | CN¥278.69 Million | +31.89% |
| 2000-12-31 | CN¥211.30 Million | -30.94% |
| 1999-12-31 | CN¥305.96 Million | +9.92% |
| 1998-12-31 | CN¥278.36 Million | +44.43% |
| 1997-12-31 | CN¥192.73 Million | -14.67% |
| 1996-12-31 | CN¥225.85 Million | -4.64% |
| 1995-12-31 | CN¥236.85 Million | +5.20% |
| 1994-12-31 | CN¥225.14 Million | -1.57% |
| 1993-12-31 | CN¥228.74 Million | -18.57% |
| 1992-12-31 | CN¥280.90 Million | +148.87% |
| 1991-12-31 | CN¥112.87 Million | +371.96% |
| 1990-12-31 | CN¥23.91 Million | +56.95% |
| 1989-12-31 | CN¥15.24 Million | -- |